Update of the Mexican College of Rheumatology Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis

Cardiel, Mario H.; Carrillo, Sandra; Pérez, María Cristina; Andrade, Lília; Tena, C. Pacheco; Silveira, Luis H.; Limón, Leonardo; Cerpa, Sergio; Ureña, Sergio Gutiérrez; Durán, Sergio; Palazuelos, Fedra Irazoque; López, Sandra; Ayala, Sandra Araceli Sicsik; Barile, Leonor; Sánchez, María Verónica Calyeca; Portes, Daniel Grajeda; Portela, Margarita; Bedolla, Alina Hernández; García‐Figueroa, José Luis; Montero, Mauricio; Abud‐Mendoza, Carlos; Martinez, M.U. Martinez; Ostdam, David Herrera van; Pascual‐Ramos, Virginia; Merayo-Chalico, Javier; Guzmán-Sánchez, Istar; Pérez-Bastidas, María Esther; Arreola, Jorge Enrique Aguilar; Rodríguez, Alejandra López; Reyes-Cordero, Greta; Ricardez, Humberto Alfredo; Cabrera, Manuel Rodrigo de la O; Olvera-Soto, Guadalupe; Friedmann, Daniel Xibillé

doi:10.1016/j.reumae.2013.10.006

Cited by 21 publications

(28 citation statements)

References 136 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this current systematic review, 8 major best practice guidelines, including ACR and EULAR, recommend ≥2 csDMARDs as monotherapy or in combination . Only the Mexican College of Rheumatology guidelines did not address this . Australia's Medicare requires a patient to have received ≥2 csDMARD for ≥3 months each at standard doses, in monotherapy or combination therapy .…”

Section: Resultsmentioning

confidence: 99%

“…The optimal duration of csDMARDs was not specified in the ACR, Mexican and Spanish guidelines. The Spanish guidelines recommend earlier bDMARDs/tsDMARDs if there are poor prognostic factors such as seropositivity, erosions or high disease activity …”

Section: Resultsmentioning

confidence: 99%

“…In renal or hepatic impairment, or advanced age, lower doses of 7.5‐10 mg/wk are considered adequate . The Canadian and Mexican guidelines recommend titrating MTX up to 25 mg/wk . APLAR advocates titrating MTX up to a “maximally tolerated dose” .…”

Section: Resultsmentioning

confidence: 99%

“…In summary, the CWG reviewed guidelines published from the following: German Society of Rheumatology, Canadian Rheumatology Association, British Society of Rheumatology/ British Health Professionals for Rheumatology (BSR/ BHPR), NICE, Mexican College of Rheumatology, Thai Rheumatism Association, Asia‐Pacific League against Rheumatism (APLAR), Spanish Society of Rheumatology, ACR, EULAR and Australia's Medicare . Recommendations are summarized in Table .…”

Section: Methodsmentioning

confidence: 99%

See 3 more Smart Citations

Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted‐synthetic therapy for the treatment of rheumatoid arthritis

et al. 2019

View full text Add to dashboard Cite

Introduction Approximately 30% of patients with rheumatoid arthritis (RA) respond inadequately to conventional‐synthetic disease‐modifying anti‐rheumatic drugs (csDMARDs). However, widespread use of biologic DMARDs (bDMARDs) and targeted‐synthetic (tsDMARDs) is limited by cost. We formulated updated recommendations for eligibility criteria for government‐assisted funding of bDMARDs/tsDMARDs for RA patients in Singapore. Materials and Methods Published guidelines regarding use of bDMARD and tsDMARDs were reviewed. We excluded those without a systematic literature review, formal consensus process or evidence grading. Separately, unpublished national reimbursement guidelines were included. Results Eleven recommendations regarding choice of disease activity measure, initiation, order of selection and continuation of bDMARD/tsDMARDs were formulated. A bDMARD/tsDMARD is indicated if a patient has: (a) at least moderately active RA with a Disease Activity Score in 28 joints/erythrocyte sedimentation rate (DAS28‐ESR) score of ≥3.2; (b) failed ≥2 csDMARD strategies, 1 of which must be a combination; (c) received an adequate dose regimen of ≥3 months for each strategy. For the first‐line bDMARD/tsDMARD, either tumor necrosis factor inhibitors (TNFi), non‐TNFi (abatacept, tocilizumab, rituximab), or tsDMARDs, may be considered. If a first‐line TNFi fails, options include another TNFi, non‐TNFi biologic or tsDMARDs. If a first‐line non‐TNFi biologic or tsDMARD fails, options include TNFi or another non‐TNF biologic or tsDMARD. For continued bDMARD/tsDMARD subsidization, a patient must have a documented DAS28‐ESR every 3 months and at least a moderate European League Against Rheumatism response by 6 months. Conclusion These recommendations are useful for guiding funding decisions, making bDMARD/tsDMARDs usage accessible and equitable in RA patients who fail csDMARDs.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted‐synthetic therapy for the treatment of rheumatoid arthritis

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The French guidelines also recommended a 2 months interval before starting TNF biologic therapy . The Mexican Rheumatology Guidelines recommends an interval of 3 weeks from initiation of TB prophylaxis to treatment with anti‐TNF therapy …”

Section: Latent Tuberculosis In Rheumatic Disease Patients Opting Formentioning

confidence: 99%

Tuberculosis and biologics in rheumatology: A special situation

et al. 2017

View full text Add to dashboard Cite

India has a huge patient burden of rheumatic diseases (RDs) including rheumatoid arthritis. The use of biologics has transformed the treatment paradigm for RD; however, biologic treatment-related infections (especially tuberculosis [TB]) are an area of potential concern for TB-endemic nations like India. Anti-tumor necrosis factor (TNF) therapy impairs the physiological TNF-mediated signaling and may cause reactivation and dissemination of latent TB infection (LTBI). Careful screening is, thus, crucial in RD patients who are about to commence anti-TNF treatment. To date, there is no consensus available for the screening, evaluation and treatment of LTBI as well as on the drug dosage and duration regimen (monotherapy or combination therapy) in the Indian population. An evidence-based algorithm for LTBI screening and management in RD patients undergoing biologic disease-modifying anti-rheumatic drug therapy is suggested in this review for Indian rheumatologists. The proposed algorithm guides physicians through a step-wise screening approach, including medical history, tuberculin skin test, interferon gamma release assay, chest radiograph and management of LTBI with isoniazid therapy or its combination with rifampicin. Further, the provided algorithm can aid the national bodies (such as National TB Control Program) in formulating recommendations for LTBI in this high-risk population.

show abstract

“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements

Palmowski

Buttgereit

Dejaco

et al. 2017

Arthritis Care & Research

View full text Add to dashboard Cite

show abstract

Update of the Mexican College of Rheumatology Guidelines for the Pharmacologic Treatment of Rheumatoid Arthritis

Cited by 21 publications

References 136 publications

Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted‐synthetic therapy for the treatment of rheumatoid arthritis

Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted‐synthetic therapy for the treatment of rheumatoid arthritis

Tuberculosis and biologics in rheumatology: A special situation

“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements

Contact Info

Product

Resources

About